The aim of the study was to develop a method for fast und reliable diagnosis of peroxisomal diseases and to facilitate differential diagnosis of cholestatic hepatopathy. For the quantification of bile acids and their conjugates as well as C 27 precursors di-and trihydroxycholestanoic acid (DHCA, THCA) in small pediatric blood samples we combined HPLC separation on a reversed phase C18 column with ESI-MS/MS analysis in the negative ion mode. Analysis was done with good precision (CV 3,7% -11.1%) and sufficient sensitivity (LOQ: 11-91 nmol/L) without derivatisation. Complete analysis of 17 free and conjugated bile acids from dried blood spots and 10µL serum samples, respectively, was performed within 12 minutes. Measurement of conjugated primary bile acids plus DHCA and THCA as well as ursodeoxycholic acid (UDC) was done in 4.5 minutes. In blood spots of healthy newborns conjugated primary bile acids were found in the range of 0.01 to 2.01 µmol/L. Concentrations of C 27 precursors were below the detection limit in normal controls. DHCA and THCA were specifically elevated in cases of peroxysomal defects and one Zellweger patient.
Introduction
Synthesis of bile acids, their hepatic secretion and intestinal reabsorption are part of a complex multistep system susceptible to functional and structural defects.
Dysfunction is observed at any age but is most frequent in newborns, especially Some infants suffering from cholestasis are treated with ursodeoxycholic acid (UDC) (2) . Defects in bile acid formation may be treated with chenodeoxycholic acid (CDC) (2) (3) . For effective surveillance of such a therapy the measurement of total bile acids, as often performed, is only of limited value. Detailed information on the concentrations of primary and secondary bile acids and their conjugates however will allow precise monitoring of therapeutic interferences.
Due to the complex nature of bile acids and their low physiological concentration accurate and sensitive quantification in small biological samples has remained a difficult task. Techniques like nuclear magnetic resonance (NMR) (4), gas chromatography, high-performance liquid chromatography (5), supercritical fluid chromatography (6), gas chromatography-mass spectrometry (7) and liquid chromatography mass spectrometry (8) (9) (10) This is a fast and simple method, worth to be further tested for the inclusion of unconjugated and non-physiological bile acids like UDC. C 27 bile acids, however
were not included. The method has been applied by the same group (Mushtaq et al. (16) ) to test the possibility of screening for cholestatic hepatobiliary disease in newborns.
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Considering these experiences we developed a method for measuring a broad spectrum of primary and secondary bile acids without derivatisation. Bile acid conjugates and C 27 bile acids were included. The method was conceived for dried blood spots or small volumes of serum. Dried blood spots are the standard samples for metabolic newborn screening and can also be used for selective screening in symptomatic infants.
Method and materials
Methanol, water (E.Merck, Germany) and acetonitrile (AppliChem, Germany)
were ultra HPLC grade, ammonium acetate (Sigma, Deisenhofen, Germany) and formic acid (AppliChem, Darmstadt, Germany) were of highest purity. Calibrators and controls were stored at -20 °C. Unspiked whole blood spots and serum were used as blanks.
Calibrators and controls

Stock
Samples
For method development serum and dried blood spots of healthy volunteers were used. For the establishment of reference and patient data we analysed anonymised blood spot material of our routine metabolic newborn and selective screening programme as well as several serum samples or dried blood spots of known patients. Blood spots were collected on filterpaper Whatman 903. The study was approved by the medical ethics review board of Hannover Medical School.
Sample preparation
For extraction of bile acids 150 µl methanolic standard solution were added to each 6 mm blood spot and 12.4 µl serum, respectively. After sealing with aluminium foil the microtitre plate (ABgene, Hamburg, Germany) was shaken for 30 minutes. 
Liquid chromatography
HPLC was done on a Luna C18 (2) 
Mass spectrometry conditions
All analyses were done on a QUATTRO Micro tandem mass spectrometer All bile acids were quantified using external calibrators. Deuterated bile acids were used as internal standards.
To determine the concentration the ratio of analyte to internal standard was used. D4-GC was used for unconjugated and glycine conjugated bile acids, d4-CA was used for calculation of CAs and unfragmented bile acids. d4-TCDC was used to determine the concentration of taurine conjugated BAs.
Precision data and statistics
Recovery 
Results
Liquid chromatography tandem mass spectrometry
Detection of qualified precursors and product ions for each bile acid and optimisation of parameters were done by direct infusion of each bile acid in methanolic solution at a concentration of 10 µmol/L into the mass spectrometer. To evaluate matrix effects the post-column infusion method was used (18). Mainly salts, 11 lipids, phospholipids and fatty acids co-elute with the analytes and may affect the ESI droplet desolvation process and influence the ionisation of the compounds of interest (19) . The pK a of free bile acids is around 6 (6). Optimal separation was obtained at a pH of 4.
Method performance
Precision
For intra-day and inter-day variation two quality control concentrations within the calibration range for each analyte were determined ( Table 2 , Supplemental Table 1 ). The intra-assay coefficient of variation (CV) for dried blood material ranged from 3.7% (taurolithocholic acid) to 11.1% (lithocholic acid). Total imprecision results yielded CV of 7.1% (glycocholic acid) to 12.6% (tauro ursodeoxycholic acid) at low concentration levels and 7.7% to 13% for the same substances at higher concentrations. Recovery of all determined bile acids from dried blood spot material averaged 66%. After extraction the limit of detection (LOD) (signal/noise ratio = 3)
varied between 4 -30 nmol/L, the limit of quantification (LOQ) (signal/noise ratio = 10) between 11 -91 nmol/L, respectively.
Linearity
Calibration curves of all bile acids from dried blood spots (see Table 2 ) were prepared sixfold and analysed in a single run. The ratio of each analyte to internal standard peak height was plotted against the analyte concentration. For all bile acids the calibration curves were linear with a regression coefficient of > 0.996.
Ion suppression
Ion suppression was evaluated analysing extracted dried blood samples injected into a flow of a bile acid standard solution inserted by a syringe pump at a 
Healthy newborns (controls)
Dried blood spots from newborns (1-3 days old) without known diseases divided into gestational age groups of 20 individuals were analysed. The medians of the groups are summarized in Table 3 . The concentrations of the bile acids TCDC, GCDC, TC, and GC decreased with increasing gestational age, the remaining bile acids showed low concentrations and no correlations with the gestational age.
During the first three days of life when the majority of blood samples are collected for newborn metabolic screening concentrations of bile acids were mostly around the detection limit of this method. Sensitivity, however, was good enough to detect any pathologically elevated concentrations. Median and 99 th percentile of free and conjugated bile acids are summarized in Table 4 . 310 samples of infants 3 to 81 days old were measured to calculate median and 99 th percentiles. These were used as reference values in Supplemental Tables 2 and 3 .
Patient samples
Patient samples were sent for selective screening in symptomatic patients.
Measurement of bile acids was done as an additional test.
A) Peroxisomal defects
Patients A-F showed increased levels of C 26 . In cases of peroxysomal defects (patients A-E, Table 5 ) DHCA and THCA were measured in significantly elevated 
B) Classical galactosemia
Among a group of infants with severe liver disease selectively screened for metabolic disease there were 8 patients suffering from classical galactosemia. They had not been tested for galactosemia during the first days of life. All patients listed in
Supplemental Table 2 showed grossly elevated concentrations of conjugated CDC and in some of the samples conjugated cholic acid was increased. Newborn screening for galactosemia had not been done except for patient 8. In this case we were able to demonstrate normal bile acid concentrations at day 3 of life but elevated concentrations a few days later when liver disease became clinically apparent. Free primary and secondary bile acids as well as C 27 precursors were found within the normal range in all cases. Three additional infants diagnosed with galactokinase deficiency did not exhibit increased bile acid concentrations (data not shown).
C) Biliary atresia
In two cases of biliary atresia we were able to compare bile acid concentrations in dried blood samples of the second day of life to those taken at an age of 60 and 118 days, respectively (Supplemental Table 3 ). Whilst the complete spectrum of bile acids was normal in those samples collected early, concentrations of the primary bile acid conjugates were strongly elevated at the second analysis. Other bile acids were not affected. 
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E) Pediatric patients on ursodeoxycholic acid treatment
Neonates and infants on treatment with ursodeoxycholic acid were tested for bile acids. They showed variable concentrations of primary bile acid conjugates as well as of the therapeutic agent and its conjugates (Supplemental Table 4 )
Discussion
The aim of this study was to provide a method for rapid quantification of C 24
and C 27 bile acids in small volumes of pediatric blood and serum samples. MS/MS cannot distinguish between molecules of identical mass/charge (m/z) relations which deliver daughter ions of identical masses. As shown in Table 1 In infants with inborn errors of metabolism dried blood spot samples are regularily used to monitor the levels of key metabolites. In diseases associated with cholestasis it may be advantageous to add bile acids to the test spectrum in order to survey liver function and bile acid circulation.
In conclusion, bile acid profiling using the method described here is useful for diagnosing and monitoring diseases affecting bile acid metabolism or circulation especially in pediatric patients. It also provides a means for the early detection of compromised bile acid metabolism including defects of the ß-oxidation of bile acid precursors. Table 5 Bile acid concentration in serum from infants with peroxysomal defects (cases A-E), genetically proven 
